- Home
- AVTX vs GDO Comparison
AVTX vs GDO Comparison
Compare AVTX & GDO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | AVTX | GDO |
|---|---|---|
| Founded | 2011 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance Companies |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 248.3M | 87.6M |
| IPO Year | 2015 | N/A |
Fundamental Metrics
Financial Performance| Metric | AVTX | GDO |
|---|---|---|
| Price | $18.99 | $11.84 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 9 | 0 |
| Target Price | ★ $32.29 | N/A |
| AVG Volume (30 Days) | ★ 341.4K | 39.4K |
| Earning Date | 11-06-2025 | 01-01-0001 |
| Dividend Yield | N/A | ★ 9.81% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $192,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.39 | $11.21 |
| 52 Week High | $20.72 | $13.04 |
Technical Indicators
Market Signals| Indicator | AVTX | GDO |
|---|---|---|
| Relative Strength Index (RSI) | 53.63 | 61.19 |
| Support Level | $17.18 | $11.63 |
| Resistance Level | $20.20 | $11.90 |
| Average True Range (ATR) | 1.60 | 0.12 |
| MACD | -0.06 | 0.02 |
| Stochastic Oscillator | 59.35 | 93.10 |
Price Performance
Historical ComparisonAbout AVTX Avalo Therapeutics Inc.
Avalo Therapeutics Inc is a clinical-stage biotechnology company focused on the treatment of immune dysregulation. The company's asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).
About GDO Western Asset Global Corporate Defined Opportunity Fund Inc.
Western Asset Global Corp Defined Opp is a closed-end management investment company with a primary investment objective to provide current income. Its secondary objective is to seek capital appreciation. The Fund invests in the United States and foreign corporate fixed-income securities of varying maturities.